Most Shorted Stocks
MRNA is part of our most shorted stocks screen list, indicating it has a high short interest.
MODERNA INC (MRNA) Stock Price & Overview
NASDAQ:MRNA • US60770K1079
Current stock price
47.14 USD
-1.56 (-3.2%)
At close:
47.14 USD
0 (0%)
Pre-Market:
The current stock price of MRNA is 47.14 USD. Today MRNA is down by -3.2%. In the past month the price decreased by -2.26%. In the past year, price increased by 70.74%.
MRNA Key Statistics
52-Week Range22.28 - 59.55
Current MRNA stock price positioned within its 52-week range.
1-Month Range46.75 - 56.2
Current MRNA stock price positioned within its 1-month range.
- Market Cap
- 18.695B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.27
- Dividend Yield
- N/A
MRNA Stock Performance
Today
-3.2%
1 Week
-13.07%
1 Month
-2.26%
3 Months
+6.97%
Longer-term
6 Months +73.56%
1 Year +70.74%
2 Years -57.27%
3 Years -64.53%
5 Years -73.64%
10 Years N/A
MRNA Stock Chart
MRNA Stock Screens
MRNA currently appears in the following ChartMill screener lists.
MRNA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MRNA. When comparing the yearly performance of all stocks, MRNA is one of the better performing stocks in the market, outperforming 87.58% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
MRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MRNA. The financial health of MRNA is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MRNA Earnings
On February 13, 2026 MRNA reported an EPS of -2.11 and a revenue of 678.00M. The company beat EPS expectations (21.71% surprise) and beat revenue expectations (6.17% surprise).
Next Earnings DateMay 1, 2026
Last Earnings DateFeb 13, 2026
PeriodQ4 / 2025
EPS Reported-$2.11
Revenue Reported678M
EPS Surprise 21.71%
Revenue Surprise 6.17%
MRNA Forecast & Estimates
30 analysts have analysed MRNA and the average price target is 45.4 USD. This implies a price decrease of -3.7% is expected in the next year compared to the current price of 47.14.
For the next year, analysts expect an EPS growth of 1.99% and a revenue growth 10.33% for MRNA
Analysts
Analysts56
Price Target45.4 (-3.69%)
EPS Next Y1.99%
Revenue Next Year10.33%
MRNA Index Membership
MRNA is currently included in the following stock indexes tracked on ChartMill.
MRNA Financial Highlights
Over the last trailing twelve months MRNA reported a non-GAAP Earnings per Share(EPS) of -7.27. The EPS increased by 21.66% compared to the year before.
Income Statements
Revenue(TTM)1.94B
Net Income(TTM)-2.82B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.87% | ||
| ROE | -32.62% | ||
| Debt/Equity | 0.07 |
Chartmill High Growth Momentum
EPS Q2Q%27.49%
Sales Q2Q%-29.81%
EPS 1Y (TTM)21.66%
Revenue 1Y (TTM)-39.93%
MRNA Ownership
Ownership
Inst Owners79.19%
Shares396.59M
Float367.57M
Ins Owners2.7%
Short Float %16.17%
Short Ratio7.55
MRNA Industry Overview
MRNA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
66%
Outperformed 66% of sub-industries
3 Month Rank
48%
Outperformed 48% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.8%
- New Lows
- 3.1%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.2
- Average Fwd P/E
- 22.5
- Average Debt/Equity
- 2.1
MRNA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.33 | 349.666B | ||
| AMGN | AMGEN INC | 14.87 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.08 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.61 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.26 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.37 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 24.944B | ||
| INCY | INCYTE CORP | 10.7 | 19.451B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MRNA
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
IPO: 2018-12-07
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Stephane Bancel
Employees: 4700
Phone: 16177146500
MODERNA INC / MRNA FAQ
What does MRNA do?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
What is the current price of MRNA stock?
The current stock price of MRNA is 47.14 USD. The price decreased by -3.2% in the last trading session.
What is the dividend status of MODERNA INC?
MRNA does not pay a dividend.
How is the ChartMill rating for MODERNA INC?
MRNA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is MODERNA INC (MRNA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MRNA.
Can you provide the number of employees for MODERNA INC?
MODERNA INC (MRNA) currently has 4700 employees.
Who owns MODERNA INC?
You can find the ownership structure of MODERNA INC (MRNA) on the Ownership tab.